Deep Vein Thrombosis Market Report 2025

The deep vein thrombosis market size has grown steadily in recent years. It will grow from $1.06 billion in 2024 to $1.1 billion in 2025 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to increased vascular medicine specialization, influence of medical guidelines, focus on thrombosis prevention, clinical research development, increased diagnosis awareness.

The deep vein thrombosis market size is expected to see steady growth in the next few years. It will grow to $1.32 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to growing aging population, rising incidence of lifestyle diseases, preventive healthcare emphasis, innovative therapies, focus on patient-centric care. Major trends in the forecast period include risk factors awareness, advancements in diagnosis, treatment innovations, public health initiatives, post-surgical prevention.

The escalating demand for deep vein thrombosis (DVT) treatment is anticipated to fuel the expansion of the DVT market in the coming years. DVT treatment involves the administration of drugs, including anticoagulants, to mitigate the formation and enlargement of blood clots in individuals with deep vein thrombosis. The growing number of patients seeking DVT treatment signals an upsurge in the prevalence of deep vein thrombosis, necessitating the development of products for DVT diagnosis, prevention, and treatment. In February 2023, the Centers for Disease Control and Prevention (CDC) reported that an estimated 900,000 people in the United States could be affected annually by deep vein thrombosis, with 60,000 to 100,000 Americans succumbing to DVT or pulmonary embolism each year. Consequently, the rising demand for DVT treatment is a key driver propelling market growth.

The increasing incidence of obesity is poised to drive the growth of the deep vein thrombosis market. Obesity, a medical condition characterized by the accumulation of excess body fat, poses various health risks and complications. DVT treatment assumes a crucial role in managing obesity, given its status as an independent and moderate risk factor for venous thromboembolism (VTE), encompassing DVT and pulmonary embolism (PE). As of March 2023, the World Heart Federation disclosed that approximately 2.3 billion adults and children globally are either obese or overweight. With the prevailing obesity trend, projections indicate that the number of individuals living with obesity will reach 2.7 billion by 2025. Hence, the mounting prevalence of obesity stands as a driving force behind the growth of the deep vein thrombosis market.

The deep vein thrombosis market is witnessing a significant trend towards product innovation, with major industry players actively integrating advanced technologies to introduce novel products and fortify their market positions. A case in point is Penumbra Inc., a renowned US-based developer specializing in groundbreaking therapies. In January 2023, the company unveiled Lightning Flash, a state-of-the-art mechanical thrombectomy system meticulously engineered to tackle venous and pulmonary thrombus challenges. This innovative system showcases Penumbra's proprietary lightning-intelligent aspiration technology alongside cutting-edge dual clot detection algorithms. Specifically designed to swiftly address substantial blood clots, including venous thrombus and pulmonary emboli (PE), Lightning Flash equips physicians with a robust, high-torque catheter optimized for the efficient removal of clot burdens in both pulmonary arteries and the deep venous system. Notably, this system upholds an exemplary safety profile, underscoring its potential as a pivotal advancement in DVT treatment modalities.

Major players in the deep vein thrombosis (DVT) market are actively engaging in strategic partnerships to expedite the diagnosis of DVT and optimize their market profitability. This strategic approach underscores a growing interest in harnessing the capabilities of artificial intelligence (AI) and machine learning to enhance medical diagnostics, particularly in the swift and precise identification of DVT. A notable example occurred in November 2023 when UK-based ultrasound AI company ThinkSono Ltd. collaborated with US-based academic medical center NYU Langone Health. Together, they initiated the first clinical trial for an innovative AI-powered ultrasound software, known as the ThinkSono Guidance System. This technology aims to revolutionize the diagnosis of DVT by leveraging AI to potentially achieve faster, more precise, and cost-effective results compared to traditional techniques. The trial involves the utilization of the ThinkSono Guidance System alongside standard ultrasound scanning in patients with and without DVT. The performance of the two approaches will be rigorously assessed to confirm the accuracy of the ThinkSono system. The trial will also benefit from the participation of medical students from the NYU Grossman School of Medicine, contributing to the practical research curriculum.

In March 2024, Pfizer Inc., a U.S.-based biopharmaceutical company, partnered with Bristol-Myers Squibb (BMS) to provide grant support for ongoing professional education focused on anticoagulation in atrial fibrillation and venous thromboembolism. This collaboration encourages organizations to apply for grants that support independent educational initiatives aimed at enhancing the understanding of oral anticoagulant treatments for patients with atrial fibrillation and venous thromboembolism. Bristol-Myers Squibb is also a U.S.-based pharmaceutical company.

Major companies operating in the deep vein thrombosis market include Abbott Laboratories, Bristol-Myers Squibb Company, Sanofi-Aventis U.S. LLC, Daiichi Sankyo Company Limited, Aspen Pharmacare Holdings Limited, Novartis AG, Mylan N.V., Bayer AG, Boehringer Ingelheim GmbH, Medtronic PLC, Hikma Pharmaceuticals PLC, Laboratorios Farmacéuticos Rovi S.A., Cardinal Health Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca PLC, Stryker Corporation, Cook Medical Incorporated, Boston Scientific Corporation, Arjo AB, DJO Global Inc., Zimmer Biomet Holdings Inc., Devon Medical Products LLC, ThermoTek USA Inc., Pfizer Inc.

North America was the largest region in the deep vein thrombosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global deep vein thrombosis market report during the forecast period. The regions covered in the deep vein thrombosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the deep vein thrombosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Deep vein thrombosis (DVT) is a serious medical condition characterized by the formation of blood clots in one or more deep veins within the body. Commonly, this condition manifests with symptoms such as swelling, pain, and tenderness in the affected area, typically the leg.

The primary categories of drugs utilized in the treatment of deep vein thrombosis include anticoagulants, inferior vena cava filters, and other therapeutic options. Anticoagulants, commonly referred to as blood thinners, are medications designed to prevent the formation of blood clots in the blood vessels. Treatment approaches for DVT encompass surgical interventions, pharmaceutical interventions, and other modalities. These treatments may be administered through various routes, including injectable, oral, and other methods. The distribution channels for these medications include hospital pharmacies, retail pharmacies, and online pharmacies. Additionally, the end-users for these drugs span diverse healthcare settings such as hospitals, homecare, specialty clinics, and others.

The deep vein thrombosis market research report is one of a series of new reports that provides deep vein thrombosis market statistics, including deep vein thrombosis industry global market size, regional shares, competitors with a deep vein thrombosis market share, detailed deep vein thrombosis market segments, market trends and opportunities, and any further data you may need to thrive in the deep vein thrombosis industry. This deep vein thrombosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The deep vein thrombosis market includes revenues earned by entities by providing services related to treatment such as blood thinning medication, thrombolytic therapy, interventional radiology therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.